Clinical trials: First Line Treatment
Biliary Tract Neoplasms
Apatinib for Advanced Biliary Carcinoma
This is a phase II open-label, one-arm, single-center study of apatinib for eligible patients with advanced biliary tract carcinoma after the first-line treatment failure. A total of 55 patients is planned for enrollment.
- Trial name
- NCT03427242
- Testing
- Apatinib
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Fudan University
Ductal Infiltrating Metastatic Breast Cancer, Hormone-receptors Positive Breast Cancer
Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers
The STIC CTC study is a randomized trial to evaluate the medico-economic interest of taking into account circulating tumor cells (CTC) to determine the kind of first line treatment for metastatic, hormone-receptors positive…
- Trial name
- NCT01710605
- Testing
- Circulating tumor cells counting at baseline
- Where
- 17 sites in France
- Volunteers
- 800 people
- Sponsor
- Institut Curie
ORR,OS,PFS
Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
Evaluation of Efficacy and Safety of Sintilimab Plus Bevacizumab and AG Regimen as First-Line Therapy in Patients with Surgically Ineligible Locally Advanced or Metastatic Cholangiocarcinoma Objectives: Primary Objective: To…
- Trial name
- NCT07328802
- Testing
- Sintilimab combined with bevacizumab and albumin-bound paclitaxel plus gemcitabine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Small Cell Lung Cancer (SCLC)
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
The purpose of this trial is to compare the effects of TAS-102 with either amrubicin or topotecan (drugs used in Small Cell Lung Cancer) on lung cancer to find out the effects on survival, how much time may pass without disease…
- Trial name
- NCT01904253
- Testing
- TAS-102, Amrubicin (Japan), Topotecan (Japan/Europe)
- Where
- 23 sites in Germany, Italy and 1 more
- Volunteers
- 18 people
- Sponsor
- Taiho Oncology, Inc.
T-cell Lymphoma
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
This study aims to evaluate the efficacy of lenalidomide associated with CHOP as measured by complete response rate at the end of treatment.
- Trial name
- NCT01553786
- Testing
- Lenalidomide
- Where
- 30 sites in Belgium, France
- Volunteers
- 80 people
- Sponsor
- The Lymphoma Academic Research Organisation
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC
Lung cancer is the leading cause of cancer deaths worldwide. It is estimated that, in 2004, 173,700 new cases of lung cancer will be diagnosed in the United States alone and 164,440 deaths due to this disease will occur(13) .
- Trial name
- Coimbra (NCT00561054)
- Testing
- CETUXIMAB
- Where
- Portugal
- Volunteers
- 47 people
- Sponsor
- Grupo Portugues de Estudo do Cancro do Pulmao
Metastatic Melanoma, Melanoma
Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
This study evaluates the effectiveness of first-line immunotherapy in patients with metastatic melanoma treated at the Institute of Oncology Ljubljana in Slovenia.
- Trial name
- NCT07407166
- Testing
- Immunotherapy
- Where
- Slovenia
- Volunteers
- 40 people
- Sponsor
- Institute of Oncology Ljubljana
Breast Cancer, Her 2 Positive Breast Cancer
Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease
The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings.
- Trial name
- PERTUREAL (NCT07542496)
- Where
- 2 sites in Algeria
- Volunteers
- 1,000 people
- Sponsor
- Société Algérienne de Formation et Recherche en Oncologie
Colorectal Neoplasms
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly.
- Trial name
- NCT00314353
- Testing
- Bevacizumab, Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- NSABP Foundation Inc
Aplastic Anaemia
HID-HSCT Versus IST as First-line Treatment for SAA
This study aims to compare the efficacy and safety of HLA-haploidentical hematopoietic stem cell transplantation (HLA-haplo HSCT) versus optimal immunosuppressive therapy (IST) as first-line treatments for severe aplastic anemia…
- Trial name
- NCT07338422
- Testing
- IST (ATG + CsA+TPORA), tranplantation
- Volunteers
- 116 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hepatocellular Carcinoma
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
- Trial name
- NCT07813572
- Testing
- ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Multiple Sclerosis
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
The main aim was to study in the real world setting the effectiveness of Cladribine tablets in terms of Annualized Relapse Rate (ARR) and disability progression, in participants who switched from a first line Disease Modifying…
- Trial name
- NCT04934800
- Testing
- Cladribine
- Where
- 61 sites in Austria, Greece and 5 more
- Volunteers
- 256 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Non-Small Cell Lung Cancer
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The study aims to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab versus chemotherapy in combination with pembrolizumab in the first-line treatment of patients with locally advanced or metastatic…
- Trial name
- NCT06711900
- Testing
- SKB264, Pembrolizumab, pemetrexed
- Where
- 81 sites in China
- Volunteers
- 432 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal…
- Trial name
- NCT07304739
- Testing
- Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Carcinoma, Squamous Cell of Head and Neck
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head…
- Trial name
- CHANGE2 (NCT02383966)
- Testing
- Cetuximab, Cisplatin/Carboplatin, 5-fluorouracil
- Where
- Germany
- Volunteers
- 243 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Penile Cancer
A PHASE II, RANDOMIZED STUDY TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT PENILE CANCER
This is a phase II, randomized study which will enroll participants given 4 to 6 cycles of first-line platinum-based chemotherapy treatment for advanced penile SCC not amenable by curative surgical treatment (stages III-IV as per…
- Trial name
- BRAVA PENILE (NCT07101822)
- Testing
- Cemiplimab
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Hospital Israelita Albert Einstein
Colorectal Carcinoma
XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.
- Trial name
- NCT00215722
- Testing
- Cetuximab
- Where
- 10 sites in Portugal
- Volunteers
- 45 people
- Sponsor
- Grupo de Investigacao do Cancro Digestivo
Marginal Zone Lymphoma(MZL)
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
The goal of this clinical trial is to learn if Zanubrutinib, Rituximab, and Lenalidomide works to treat marginal zone lymphoma as the first-line therapy. It will also learn about the safety of the treatment.
- Trial name
- NCT07299331
- Testing
- Zanubrutinib, Rituximab, and Lenalidomide as first-line treatment for Marginal Zone Lymphoma, Zanubrutinib, Rituximab, and Lenalidomide as the primary treatment for Marginal Zone Lymphoma
- Volunteers
- 50 people
- Sponsor
- Zhengzhou University
Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase
The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid Cancer
The psychosomatic symptoms of patients with differentiated thyroid cancer (DTC) during the initial treatment phase need to be improved.
- Conditions
- Pathologically Confirmed Differentiated Thyroid Carcinoma, All Patients Are in the Initial Treatment Phase, Normal Cognitive and Communicative Abilities, Capable of Reading and Understanding Questionnaires in Chinese, Ability to Use a Smartphone
- Trial name
- NCT06422702
- Testing
- Psychosomatic Symptoms Intervention, Extended supportive care
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Harbin Medical University
Biliary Tract Carcinoma
Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
This study will evaluate the efficacy and safety of 1st line therapy with gemcitabine plus S1 and tislelizumab in participants with advanced biliary tract carcinoma (BTC).
- Trial name
- NCT05822453
- Testing
- Gemcitabine, S1, Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.